Is Recipharm on the cusp of becoming a leading inhalation company?19 Nov 2019
The CDMO offers to acquire Consort Medical to become a Top Five global CDMO player.
Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort, a leading global drug delivery and device company and integrated CDMO. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of £505 million (approximately SEK 6,284 million0.
Recipharm’s aim is to become a leading global CDMO and it is successfully executing against its ambitious growth strategy, targeting annual sales of over SEK 8 billion by 2020. This target has been set amid consolidation in the fragmented CDMO industry, as pharmaceutical companies seek to reduce their fixed costs by rationalising supply chains and focusing on core R&D and sales capabilities. Consequently, they are turning to trusted partners with the necessary scale and breadth of technologies to support them through the drug development process and the subsequent commercial manufacturing and supply.
Given these sector dynamics, and Consort’s strength in pharmaceutical device development and manufacturing, Recipharm believes that the combination is an excellent match. Recipharm has been an admirer of Consort’s innovative delivery technologies, which are highly complementary to Recipharm’s capabilities in the development and commercial supply of both inhaled and sterile injectable finished dose forms. The Aesica division provides expansion through additional capabilities and access to new customers. The combination of Consort’s product portfolio and services with Recipharm’s existing business will allow the enlarged organisation to become a best-in-class technology-based CDMO, positioning it to compete more effectively within a wider part of the value chain.
Commenting on the transaction, Thomas Eldered, CEO of Recipharm, said: “I am excited at the prospect of combining Recipharm with Consort, which is extremely complementary. In our view, Bespak is already acknowledged as a leading drug device developer and manufacturer and is a perfect fit for Recipharm’s broader pharmaceutical capabilities. The enlarged group will be able to provide finished dose forms in Bespak’s key technologies and provide customers with a far more integrated approach. The Aesica business will further expand our capabilities and capacities in both API and finished dose manufacturing whilst providing access to a new customer base”.
Commenting on the transaction, Christopher Brinsmead CBE, Chairman of the Board of Consort, said: “Consort’s leading technologies and market positions provide innovative solutions and products to a blue-chip customer base. We believe that Recipharm’s businesses are highly complementary to our own and the Board intends to unanimously recommend the offer from Recipharm which represents a 39% premium to our share price”.
Jonathan Glenn, CEO, of Consort added: “Consort’s strategy has been to focus on expanding its businesses into new markets and geographic territories, and on developing our combined drug/device offering. Recipharm’s capabilities and footprint in drug manufacturing will enhance both our Bespak and Aesica businesses. We believe that customers of both businesses will value the offering and enhanced scale of the combined business”.
Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment
4 Dec 2019
Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.Read more
Connectivity, customization and sustainability driving packaging and drug delivery in 2020
4 Dec 2019
Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.Read more
Eli Lilly unveils shared innovation laboratory in San Francisco
3 Dec 2019
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.Read more
Ground-breaking work creates novel oil-in-water nanoemulsions
3 Dec 2019
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.Read more
UK experiences a 'baby boom' of new life sciences ventures
2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.Read more
Pinpoint secures new investment to develop "ground-breaking" products
29 Nov 2019
The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.Read more
New single-use mixing system offers rapid and homogenous mixing
28 Nov 2019
ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.Read more
Worldwide event predicts global pharma trends for 2020
27 Nov 2019
Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.Read more
UK’s life sciences sector continues to attract talent despite Brexit fear
26 Nov 2019
The largest area of growth has been within biotechnology companies, where job openings increased by 35%.Read more
Dr Reddy’s enters Nutrition Segment with diabetes drink
25 Nov 2019
The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation